Why does it matter if a kidney disease is complement-driven or complement-associated?

Dr. Matthew Pickering (Imperial College London, United Kingdom) explains this critical distinction and why it changes how clinicians approach diagnosis and treatment. The discussion explores promising new therapies such as C3 and C5 inhibitors and how biomarkers are paving the way for precision medicine in nephrology.

This episode is part of a four-part KDIGO Conversations in Nephrology series on complement-mediated kidney diseases, hosted by Dr. Carla Nester (University of Iowa Stead Family Children’s Hospital, United States).

This series was supported by Apellis and Sobi.